Literature DB >> 20887198

Hepcidin and disorders of iron metabolism.

Tomas Ganz1, Elizabeta Nemeth.   

Abstract

The hepatic peptide hormone hepcidin is the principal regulator of iron absorption and its tissue distribution. Pathologically increased hepcidin concentrations cause or contribute to iron-restrictive anemias including anemias associated with inflammation, chronic kidney disease and some cancers. Hepcidin deficiency results in iron overload in hereditary hemochromatosis and ineffective erythropoiesis. The hepcidin-ferroportin axis is the principal regulator of extracellular iron homeostasis in health and disease, and is a promising target for the diagnosis and treatment of iron disorders and anemias.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20887198     DOI: 10.1146/annurev-med-050109-142444

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  174 in total

Review 1.  The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Known and potential roles of transferrin in iron biology.

Authors:  Thomas Benedict Bartnikas
Journal:  Biometals       Date:  2012-08       Impact factor: 2.949

3.  Stromal-derived IL-6 alters the balance of myeloerythroid progenitors during Toxoplasma gondii infection.

Authors:  David B Chou; Brian Sworder; Nicolas Bouladoux; Cindy N Roy; Amiko M Uchida; Michael Grigg; Pamela G Robey; Yasmine Belkaid
Journal:  J Leukoc Biol       Date:  2012-04-09       Impact factor: 4.962

4.  Novel tools for the evaluation of iron metabolism.

Authors:  Léon Kautz; Elizabeta Nemeth
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

Review 5.  Murine mutants in the study of systemic iron metabolism and its disorders: an update on recent advances.

Authors:  Thomas B Bartnikas; Mark D Fleming; Paul J Schmidt
Journal:  Biochim Biophys Acta       Date:  2012-01-28

6.  Inhibition of hepcidin transcription by growth factors.

Authors:  Julia B Goodnough; Emilio Ramos; Elizabeta Nemeth; Tomas Ganz
Journal:  Hepatology       Date:  2012-06-18       Impact factor: 17.425

7.  Iron homeostasis in pregnancy and spontaneous abortion.

Authors:  Yifan Guo; Na Zhang; Daoqiang Zhang; Quanzhong Ren; Tomas Ganz; Sijin Liu; Elizabeta Nemeth
Journal:  Am J Hematol       Date:  2018-11-26       Impact factor: 10.047

8.  Suppression of ferroportin expression by cadmium stimulates proliferation, EMT, and migration in triple-negative breast cancer cells.

Authors:  Zhongguo Shan; Zhengxi Wei; Zahir A Shaikh
Journal:  Toxicol Appl Pharmacol       Date:  2018-07-17       Impact factor: 4.219

Review 9.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

10.  Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.